| Selling sickness: the pharmaceutical industry and disease mongeringCommentary: Medicalisation of risk factors R Moynihan, P CG, I Heath, D Henry Bmj 324 (7342), 886-891, 2002 | 1675 | 2002 |
| Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review R Moynihan, S Sanders, ZA Michaleff, AM Scott, J Clark, EJ To, M Jones, ... BMJ open 11 (3), e045343, 2021 | 1435 | 2021 |
| Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients R Moynihan, A Cassels Greystone Books, 2008 | 1076 | 2008 |
| Preventing overdiagnosis: how to stop harming the healthy R Moynihan, J Doust, D Henry Bmj 344, e3502, 2012 | 954 | 2012 |
| Coverage by the news media of the benefits and risks of medications R Moynihan, L Bero, D Ross-Degnan, D Henry, K Lee, J Watkins, C Mah, ... New England journal of medicine 342 (22), 1645-1650, 2000 | 740 | 2000 |
| The making of a disease: female sexual dysfunction R Moynihan Bmj 326 (7379), 45-47, 2003 | 677 | 2003 |
| The fight against disease mongering: generating knowledge for action R Moynihan, D Henry PLoS medicine 3 (4), e191, 2006 | 447 | 2006 |
| Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement R Moynihan Bmj 326 (7400), 1189-1192, 2003 | 433 | 2003 |
| Too much medicine?: Almost certainly R Moynihan, R Smith BMJ 324 (7342), 859-860, 2002 | 404* | 2002 |
| Key opinion leaders: independent experts or drug representatives in disguise? R Moynihan Bmj 336 (7658), 1402-1403, 2008 | 278 | 2008 |
| Evidence-informed health policy 2–Survey of organizations that support the use of research evidence JN Lavis, EJ Paulsen, AD Oxman, R Moynihan Implementation Science 3 (1), 54, 2008 | 246* | 2008 |
| Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States RN Moynihan, GPE Cooke, JA Doust, L Bero, S Hill, PP Glasziou PLoS medicine 10 (8), e1001500, 2013 | 236 | 2013 |
| Too much medicine; too little care P Glasziou, R Moynihan, T Richards, F Godlee Bmj 347, 2013 | 233 | 2013 |
| Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased R Moynihan, R Glassock, J Doust Bmj 347, 2013 | 220 | 2013 |
| Mapping the drivers of overdiagnosis to potential solutions T Pathirana, J Clark, R Moynihan Bmj 358, 2017 | 197 | 2017 |
| Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement R Moynihan Bmj 326 (7400), 1193-1196, 2003 | 190 | 2003 |
| Words do matter: a systematic review on how different terminology for the same condition influences management preferences B Nickel, A Barratt, T Copp, R Moynihan, K McCaffery BMJ open 7 (7), e014129, 2017 | 189 | 2017 |
| Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much R Moynihan, D Henry, KGM Moons PLoS medicine 11 (7), e1001655, 2014 | 131 | 2014 |
| The marketing of a disease: female sexual dysfunction R Moynihan Bmj 330 (7484), 192-194, 2005 | 130 | 2005 |
| Sex, lies, and pharmaceuticals: how drug companies plan to profit from female sexual dysfunction R Moynihan, B Mintzes Greystone Books Ltd, 2010 | 126 | 2010 |
David HenryHonorary, Bond University, UNSW and UMelbourne, Australia; Emeritus, ICES and UToronto, CanadaVerified email at bond.edu.au
